회사소개
Imnewrun (read as “I am new run”) Biosciences inc. develops novel therapeutics for the treatment of brain disease including neurodegenerative disease, brain or brain metastatic cancer, monogenic CNS disease and lysosomal storage disease. The company has unique sets of platform technologies including but not limited as follow:
(1) blood-brain barrier penetrating peptide via receptor mediated transcytosis,
(2) cell penetrating peptide via adsorptive-mediated transcytosis, and
(3) CNS penetrating targeted RNAi delivery system.
Upon its reception in April 2019, the company successfully closed 9M USD seed round in July 2019 invested by Yuhan Corporation and SKKU, a leading pharmaceutical company and a leading university in Korea, respectively. The company’s headquarters & its research labs are strategically located within SKKU campus to form truly an integrated and interactive partnering platform. Our mission is to advance biomedical research by disruptive innovation at the cutting edge and to develop novel therapies for the treatment of patients who suffer from brain-related disorders.
인재상
The candidate must be highly motivated and possess the ability to work productively in a fast-paced environment that requires a high level of communication (proficiency in English preferred), organization, and collaboration.
.jpg)
